Rethinking Infection Diagnostics in Cystic Fibrosis - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Rethinking Infection Diagnostics in Cystic Fibrosis

A dedicated syndicate is connecting academia, industry, and people with cystic fibrosis to advance diagnostic research

  • By

  • Mollie Spindler

  • September 17, 2026

  • 6 min

Share

Clinical Scorecard: Rethinking Infection Diagnostics in Cystic Fibrosis

At a Glance

CategoryDetail
ConditionCystic Fibrosis
Key MechanismsThick, sticky mucus buildup leading to bacterial infections.
Target PopulationIndividuals with cystic fibrosis, approximately 162,000 worldwide.
Care SettingClinical settings focusing on respiratory infection management.

Key Highlights

  • CFTR modulator therapies have transformed care but altered diagnostic needs.
  • Reduced sputum production complicates traditional sputum culture diagnostics.
  • New diagnostic approaches are needed for early infection detection.
  • Innovative diagnostics may utilize alternative sample types like breath and blood.

Guideline-Based Recommendations

Diagnosis

  • Develop new diagnostic tools that provide actionable information.

Management

  • Utilize diagnostics to distinguish between active infections and chronic colonization.

Monitoring & Follow-up

  • Implement faster diagnostic approaches to identify pulmonary exacerbations.

Risks

  • Failure to adapt diagnostics may lead to delayed recognition of health deterioration.

Patient & Prescribing Data

Individuals with cystic fibrosis experiencing respiratory infections.

CFTR modulators improve outcomes but do not cure CF.

Clinical Best Practices

  • Engage with the CF AMR Syndicate for insights on unmet diagnostic needs.
  • Consider alternative sample types for more effective diagnostics.

Related Resources & Content

Original Source(s)

Rethinking Infection Diagnostics in Cystic Fibrosis

  • by Mollie Spindler

  • September 17, 2026

Related Content

ECP 2026: Is HPV-Specific Testing Optimized in Throat Cancer?

Cost and turnaround times are a potential challenge to standardization of testing and optimization of patient pathways

  • September 14, 2026

  • 2 min
Triple-positive profile may flag adverse prostate cancer pathology

A combination of PSA density, MRI, and PSMA PET findings identified a small subgroup with adverse pathology, supporting further study of biopsy-sparing pathways.

Urine Bladder Cancer Test Could Triage Cystoscopy

Real-world UK study suggests molecular testing could help prioritize patients with hematuria for urgent bladder investigation

  • September 11, 2026

  • 2 min